 The study will evaluate the effect on cells and clinical response to study medications: Epidermal Growth Factor Receptor EGFR, Tyrosine Kinase Inhibitor Erlotinib OSI-774, TarcevaTM, and Cyclooxygenase-2 COX-2 Inhibitor Celecoxib. The side effects of the medications will be assessed, and chemicals in the cells will be evaluated both before and after medication is administered that may show how the drugs work. This information will help researchers determine whether additional studies with these drugs should be conducted to determine if the drugs can help prevent pre-cancerous lesions from becoming cancerous. 